G1 Therapeutics Inc Stock News

RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, will host a webcast and conference call to provide a financ

G1 Therapeutics is a biopharmaceutical company that develops and commercializes advanced oncology treatments. Its flagship product, Cosela, is an FDA-approved drug for reducing chemotherapy side effec

G1 Therapeutics (GTHX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.73 per share a year ago.

RESEARCH TRIANGLE PARK, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financia

G1 Therapeutics (NASDAQ: GTHX ) stock is falling hard on Tuesday after the biopharmaceutical company provided an interim update on a Phase 3 clinical trial of trilaciclib as a breast cancer treatmen

G1 Therapeutics has provided pipeline updates, including encouraging preliminary overall survival data from a phase 2 study of trilaciclib in combination with sacituzumab govitecan for advanced triple

Penny stocks, securities with share prices under $5, offer investors a chance at exponential returns with little upfront investment. However, investing wisely in penny stocks requires research as thei

G1 Therapeutics, Inc. (NASDAQ:GTHX ) Q3 2023 Earnings Conference Call November 1, 2023 8:30 AM ET Company Participants Will Roberts – Vice President-Communications Jack Bailey – Chief Executive Of

Ready to dive into the volatile world of penny stocks? You've got your work cut out for yourself if this is your first foray into the stock market.

RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Communications Officer Will Robert

G1 Therapeutics (GTHX) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of a loss of $0.17 per share. This compares to loss of $0.92 per share a year ago.

RESEARCH TRIANGLE PARK, N.C., July 31, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it will participate in two August invest

GTHX halted the CRC trial on low survival benefits. There are reasons its other trials with trilaciclib could be more positive.

G1 Therapeutics (GTHX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $1.15 per share a year ago.

RESEARCH TRIANGLE PARK, N.C., April 26, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financi